Versant Venture Management, LLC Buys Passage Bio Inc, Sells CRISPR Therapeutics AG, Inari Medical Inc, Ocular Therapeutix Inc

May 07, 2021

San Francisco, CA, based Investment company Versant Venture Management, LLC (Current Portfolio) buys Passage Bio Inc, sells CRISPR Therapeutics AG, Inari Medical Inc, Ocular Therapeutix Inc, Flexion Therapeutics Inc, Akero Therapeutics Inc during the 3-months ended 2021Q1, according to the most recent filings of the investment company, Versant Venture Management, LLC. As of 2021Q1, Versant Venture Management, LLC owns 11 stocks with a total value of $513 million. These are the details of the buys and sells.

New Purchases: PASG,
Added Positions: ADVM,
Reduced Positions: CRSP, FLXN, AKRO, APRE,
Sold Out: NARI, OCUL,

For the details of Versant Venture Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/versant+venture+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Versant Venture Management, LLC

CRISPR Therapeutics AG (CRSP) - 1,554,960 shares, 36.92% of the total portfolio. Shares reduced by 48.86%
Passage Bio Inc (PASG) - 4,959,769 shares, 16.89% of the total portfolio. New Position
Aligos Therapeutics Inc (ALGS) - 3,292,339 shares, 14.59% of the total portfolio.
Adverum Biotechnologies Inc (ADVM) - 5,068,233 shares, 9.74% of the total portfolio. Shares added by 1.29%
Gritstone Bio Inc (GRTS) - 4,450,638 shares, 8.18% of the total portfolio.

New Purchase: Passage Bio Inc (PASG)

Versant Venture Management, LLC initiated holding in Passage Bio Inc. The purchase prices were between $16.24 and $29.83, with an estimated average price of $21.35. The stock is now traded at around $17.350000. The impact to a portfolio due to this purchase was 16.89%. The holding were 4,959,769 shares as of 2021-03-31.

Sold Out: Inari Medical Inc (NARI)

Versant Venture Management, LLC sold out a holding in Inari Medical Inc. The sale prices were between $77.91 and $125.92, with an estimated average price of $103.98.

Sold Out: Ocular Therapeutix Inc (OCUL)

Versant Venture Management, LLC sold out a holding in Ocular Therapeutix Inc. The sale prices were between $15.82 and $22.11, with an estimated average price of $19.26.

Here is the complete portfolio of Versant Venture Management, LLC. Also check out:

1. Versant Venture Management, LLC's Undervalued Stocks
2. Versant Venture Management, LLC's Top Growth Companies, and
3. Versant Venture Management, LLC's High Yield stocks
4. Stocks that Versant Venture Management, LLC keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.